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Abstract: Influenza A virus is a major global pathogen of humans, and there is an unmet need for
effective antivirals. Current antivirals against influenza A virus directly target the virus and are
vulnerable to mutational resistance. Harnessing an effective host antiviral response is an attractive
alternative. We show that brief exposure to low, non-toxic doses of thapsigargin (TG), an inhibitor
of the sarcoplasmic/endoplasmic reticulum (ER) Ca2+ ATPase pump, promptly elicits an extended
antiviral state that dramatically blocks influenza A virus production. Crucially, oral administration
of TG protected mice against lethal virus infection and reduced virus titres in the lungs of treated
mice. TG-induced ER stress unfolded protein response appears as a key driver responsible for
activating a spectrum of host antiviral defences that include an enhanced type I/III interferon response.
Our findings suggest that TG is potentially a viable host-centric antiviral for the treatment of influenza
A virus infection without the inherent problem of drug resistance.
Keywords: thapsigargin; endoplasmic reticulum stress; unfolded protein response; antiviral;
influenza A virus; innate immunity
1. Introduction
There is no entirely satisfactory antiviral treatment for influenza A infections. By directly targeting
the highly mutable virus, current and near-market antivirals are inherently susceptible to virus
resistance [1,2]. Thus, there is an unmet need for antivirals to be clinically effective and less vulnerable
to viral mutation. An alternative antiviral approach is to target host factors that facilitate virus
replication or promote host immune response [3,4]. Two distinct advantages underpin host-dependent
therapies: they (i) do not directly target the virus proteins, thereby reducing selection pressure and
the likelihood of drug resistant escape mutants and (ii) can target host factors shared by different
viruses [5–7]. Therefore, harnessing an effective host antiviral response is potentially a better alternative
or even a replacement for existing antivirals.
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Thapsigargin (TG) is an inhibitor of the sarcoplasmic/endoplasmic reticulum calcium (Ca2+)-
ATPase (SERCA) pump; it impedes the replenishment of Ca2+ in the endoplasmic reticulum (ER) store
resulting in net loss of Ca2+ from the ER [8]. ER Ca2+ efflux triggers ER stress [9], which involves
the unfolded protein response (UPR) that serves to restore ER function and promote cellular survival
but under extreme and prolonged stress it can also induce apoptosis. The UPR is orchestrated by
three ER resident mediators, activating transcription factor 6 (ATF6), PKR-like ER kinase (PERK),
and inositol-requiring enzyme 1 (IRE1) [10,11]. The ER stress response has been found to facilitate
virus replication. Influenza A virus replication was reported to be impeded by inhibiting the IRE1
pathway [12]. Foot-and-mouth disease (FMD) virus activates PERK to suppress antiviral type I and III
interferon (IFN) response [13]. However, ER stress-activated IRE1α also promotes antiviral RIG-I-IFN-β
signalling [14–17]. Thus, the role of TG mediated ER stress on host innate immunity affecting influenza
A virus replication is unclear. Here, we report on the discovery that low non-cytotoxic doses of TG elicit
an extended antiviral state against influenza virus replication in respiratory epithelial cells, including
primary normal human bronchial epithelial (NHBE) cells, and that its oral administration protects mice
against an otherwise lethal virus challenge. We show that TG-induced ER stress leading to UPR is a key
innate immune driver that mediates a range host-centric antiviral processes to block virus replication.
2. Materials and Methods
2.1. Cells and Influenza A Viruses
Primary NHBE cells from three different donors and bronchial epithelial growth media were
supplied by Promocell. Immortalised neonatal porcine tracheal epithelial (NPTr) cells, MDCK cells,
and Vero cells were cultured in DMEM-Glutamax supplemented with 10% foetal calf serum (FCS) and
100 U/mL penicillin-streptomycin (P/S). Human USSR H1N1 (A/USSR/77), A/Puerto Rico/8/1934 H1N1
(PR8), A/equine/Newmarket/5/03 (H3N8) and A/canine/New York/51864/2008 (H3N8) viruses were
used in this study. All viruses were propagated in 10-day-old embryonated chicken eggs, and allantoic
fluid was harvested at 72 h post-inoculation. Virus was aliquoted and stored in −80 ◦C until further use.
2.2. Cell Viability and Caspase 3/7 Assays
Cell viability based on the detection of ATP was determined using a CellTiter-Glo Luminescent
Cell Viability Assay kit (Promega, Madison, Wisconsin, USA), and activated caspase 3 and 7 were
quantified using a Caspase-Glo 3/7 Assay kit (Promega), according to manufacturer’s instructions.
Continuous monitoring of cell viability was performed using a RealTime-Glo™ MT Cell Viability
Assay (Promega) kit (Promega) according to the manufacturer’s instructions.
2.3. Chemical Priming of Cells
TG and tunicamycin (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in DMSO according to
manufacturer’s recommendations. The selected concentrations for their antiviral use were chosen for
no detectable adverse effect on cell viability. For pre-infection chemical priming, cells were cultured
in the presence of the indicated chemical, diluted in the appropriate cell culture media for 30 min,
unless otherwise indicated, rinsed three times with PBS, and followed by influenza virus infection
as described.
2.4. Infection and Progeny Virus Quantification
Infection medium of NPTr cells was Ultraculture medium (Lonza, Basel, Switzerland)
supplemented with 100 U/mL P/S, 2 mM glutamine and 250ng/mL l-1-tosylamide-2-phenylethyl
chloromethyl ketone (TPCK) trypsin (Sigma-Aldrich). Infection medium of MDCK and Vero cells was
OptiMEM (Thermo Fisher Scientific, Waltham, Massachusetts, USA) supplemented with 100 U/mL
P/S and 200 ng/mL TPCK trypsin. Infection medium of NHBE cells was bronchial epithelial growth
medium (Promocell, Heidelberg, Germany) supplemented with 125 ng/mL TPCK trypsin. Cells were
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infected at specified multiplicity of infection (MOI) of influenza virus, based on 6 h focus forming assay
(FFA), for 2 h in infection media, after which they were rinsed three times with PBS and incubated in
fresh infection media for a further 22 h. MOI of 1.0 is the minimum volume of virus needed to infect
all MDCK cells in a culture well. Quantification of infectious virus in spun culture supernatants by
FFA was conducted as previously described [18], which was an immuno-cytochemical assay based on
infection of MDCK cells with harvested supernatants for 6 h followed by immunodetection of viral
nucleoprotein (NP). Briefly, MDCK cells infected for 6 h were fixed in acetone methanol for 10 min
followed by peroxidase treatment for 10 min and incubation with a 1:8000 dilution of primary mouse
monoclonal antibody to influenza nucleoprotein (Abcam, ab20343, Cambridge, UK) for 40 min at room
temperature. The cells were subsequently rinsed with Tris-buffered saline (TBS), incubated with horse
radish peroxidase-labelled polymer for 40 min. After rinsing with TBS, the cells were incubated with
DAB substrate-chromogen solution for 7 min (Envision+ system-HRP kit, Dako, Glostrup, Denmark).
Cells positive for viral nucleoprotein were counted with an inverted microscope, and the mean of
positive cells in five 96-wells was used to calculate infectious focus-forming units of virus per microlitre
of infection volume. H3N8 progeny virus output was determined by TCID50 assay, based on 10-fold
diluted spun sns to infect MDCK cells for 48 h in a 96-well format followed by hemagglutination and
results presented as log10(TCID50/mL), based on Reed and Muench (1938) [19].
2.5. RNA Preparation and Real-Time RT-PCR
Total RNA was extracted from cells using the RNeasy Plus Minikit (Qiagen, Hilden, Germany).
Viral RNA in the spun culture supernatants was extracted with the QIAamp Viral RNA Mini Kit
(Qiagen). cDNA was synthesised from 0.5 or 1 µg of total RNA using Superscript III First Strand
synthesis kit (Thermo Fisher Scientific). Expression of host genes was performed with a LightCycler−96
instrument (Roche, Basel, Switzerland), and computation was based on the comparative Ct approach,
normalised to 18S ribosomal RNA. Human ER stress primers for HSPA5 (FH1_HSPA5 and RH1_HSPA5),
HSP90B1 (FH1_HSP90B1 and RH1_HSP90B1) and DDIT3 (FH1_DDIT3 and RH1-DDIT3), human OAS1
primers (FH1_OAS1 and RH1_OAS1), and human IFNB1 (FH1_IFNB1 and RH1_IFNB1) were pre-made
designs from Sigma-Aldrich. Primers (synthesised by Sigma-Aldrich) for USSR H1N1 M-gene, human
RIG-I (DDX58), IFNL2 and IFNL3 for pig RIG-I and OAS1 were designed using PrimerExpress 3.0.1
(Thermo Fisher Scientific); sequences described in Table 1. Human IRF9 and OAS3, and pig ER stress
primers for HSPA5, HSP90B1 and DDIT3 were pre-made designs from Sigma-Aldrich.
Table 1. Primer sequences.
Gene Sense Primer (5′–3′) Antisense Primer (5′–3′)
18S ribosomal RNA (universal) ACGGCTACCACATCCAAGGA CCAATTACAGGGCCTCGAAA
RIG-I (human) GAAGGCATTGACATTGCACAGT TGGTTTGGATCATTTTGATGACA
IFNL2 (human) GACCCAGCCCTGGTGGAC GCTGGATACAGGCCCGGAA
IFNL3 (human) GACCCAGCCCTGGGGGAT GCTGGATACAGGCCCGGAG
RIG-I (pig) CCCTGGTTTAGGGACGATGAG AACAGGAACTGGAGAAAAGTGA
OAS1 (pig) GAGCTGCAGCGAGACTTCCT GGCGGATGAGGCTCTTCA
M-gene (USSR H1N1) AGATGAGCCTTCTAACCGAGGTCG TGCAAAAACATCTTCAAGTCTCTG
2.6. Western Blotting
Cells were lysed by radioimmunoprecipitation assay (RIPA) buffer (Santa Cruz, Dallas, TX,
USA) supplemented with 1% phenylmethylsulfonyl fluoride (PMSF) (Santa Cruz), 1% inhibitor
cocktail, and 1% sodium orthovanadate, according to manufacturer’s instructions (Santa Cruz).
Protein concentration was determined by Bio-RAD protein assay (Bio-Rad, Hercules, CA, USA).
Primary antibodies were goat antiviral M1 at 1:500 dilution (Abcam, ab20910), rabbit antiviral NP at
1:500 dilution (Thermo Fisher Scientific, PA5-32242) and mouse anti-β-actin at 1:10,000 (Sigma-Aldrich,
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A5316), and appropriate species-specific secondary antibodies were peroxidase-conjugated for
chemiluminescence detection (Amersham ECL Western Blotting Detection Reagent, Marlborough,
MA, USA).
2.7. Confocal microscopy
NHBE cells were cultured in an eight well µ-slide (ibidi) and at ~70% confluence primed with
0.01 µM TG or DMSO for 30 min. Cells were washed with PBS and infected with USSR H1N1 virus at
1.0 MOI for 6 h; they were then washed twice with PBS and fixed in fresh 4% paraformaldehyde in PBS,
adjusted to pH 7.4, for 20 min at room temperature. The cells were permeabilised with 0.1% Triton
X-100 (Sigma-Aldrich) for 5 min at 4 ◦C. After washing with PBS, the samples were incubated in PBS
supplemented with 3% BSA and 1% glycine for 30 min in a humidified chamber at room temperature,
washed twice with PBS (5 min each time) and incubated under the same conditions in 10% serum
with a secondary antibody donor, diluted in PBS. The samples were incubated with the primary
antibody anti-Influenza A Virus nucleoprotein antibody (AA5H) at 6 µg/mL, Abcam) diluted in 10%
serum in PBS, overnight at 4 ◦C. The samples were washed with PBS and the secondary antibody
(anti-mouse IgG H&L Alexa Fluor® 488, Thermo Fisher Scientific) at 2 µg/mL, diluted in 10% serum in
PBS, was added for 1 h at room temperature in a humidified chamber. The secondary antibody was
removed and the cells thoroughly washed with PBS. After immunostaining for all of the proteins of
interest, the cells were washed thoroughly with PBS. ProLong™ Gold Antifade Mountant with DAPI
(Invitrogen) was added to each well at a sufficient volume to cover the base of the well and incubated
at room temperature for 24 h. The NHBE cells were subsequently stored at 4 ◦C until imaging with a
Leica TCS SP8 confocal microscope using a 63-time oil immersion objective. Integrated density was
measured using Image J 1.x [20].
2.8. Influenza Virus Challenge in Mice
To assess the antiviral function of TG in vivo, 6- to 8-week-old BALB/c mice (female) were organised
into three separate groupings to determine: post-infection survival (n = 10 for each of 2 groups),
progeny virus production (n = 6 for each of 2 groups), and changes in immuno-histopathology (n = 6 for
each of 2 groups). Each mouse was treated with 30 ng of TG or control PBS-DMSO (percentage DMSO
in PBS-DMSO and TG was the same) by gavage 12 h prior to intranasal infection with 1 × 102 TCID50
of PR8 virus (~4 times LD50 dose) PBS at 50 µL or with mock PBS control as previously described [21].
The dose of TG selected was based on a preliminary in vivo study and was well tolerated by the mice.
Subsequently, mice were given the same daily dose of TG or PBS-DMSO by gavage until 7 days dpi.
Mouse survival and body weight were monitored daily. Lungs of three mice from each TG treated
group and three from each PBS-DMSO group were collected 3 dpi, and again 5 dpi, for viral titre
determination and immuno-histopathology. Virus titration was performed by TCID50 assays on MDCK
cells inoculated with 10-fold serially diluted homogenised lung tissues and incubated at 37 ◦C in a 5%
CO2 atmosphere for 72 h. TCID50 values were calculated according to the Reed-Muench method [19].
Lung sections were incubated with anti-nucleoprotein (NP) antibody (1:100 dilution; Abcam ab20343)
at 4 ◦C overnight in a humidified chamber, then incubated with horseradish peroxidase-conjugated
secondary antibody for 60 min at room temperature. Signal was detected using the Vector Elite ABC
Kit (Vectastain, Vector Laboratories, Burlingame, CA, USA). Lung sections were also stained with
hematoxylin and eosin.
2.9. RNA-Sequencing
At greater than 80% confluence, NHBE cells were primed with 0.01 µM TG or DMSO control for 30
min, washed with PBS and infected with USSR H1N1 virus at 0.8 MOI for 12 h. Total RNA extraction
was performed using the RNeasy Plus Mini Kit (Qiagen) and ribosomal RNA depletion was applied.
For each treatment condition, a total of four samples were used for RNA-seq, comprising two technical
replicates of two biological replicates (from two donors). TruSeq Stranded Total RNA libraries were
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generated using ribosomal-depleted total RNA and sequenced using a HiSeq 3000 System (SCIF NGS
Facility). Adaptor sequences were removed using skewer v0.2.2. Reads were filtered to have average
quality score of 20 or greater, and the 3′ ends were filtered to have a quality score of 3 or greater.
The human transcriptome, containing human mRNAs and non-coding RNAs, was downloaded from
Ensembl 92 (GRCh38.p12). Influenza virus sequences were downloaded from the OpenFlu database
for the OpenFlu Isolate IDOFL_ISL_21018 (A/USSR/90/1977), last updated 2016-11-30. Sequence
alignment and read quantification was performed using the pseudo-alignment-based tool Kallisto
v0.43.0 [22]. Differential expression was determined using Sleuth v0.28.1 [23]. Differentially expressed
genes were analysed using the KEGG pathways database [24] described via NIPA (version 0.6.5)
(available from https://github.com/ADAC-UoN/NIPA), and by Ingenuity pathway analysis (IPA,
Qiagen). The RNA-seq data generated during this study are available at GEO (GSE120730).
2.10. Quantification and Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7 and the statistical method used
described in the figure legend. p-value < 0.05 was considered significant, * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001. Kaplan-Meier method was employed for survival analysis. For RNA-seq
analysis, transcripts with a false detection rate corrected p-value < 0.05 and a log2-fold change
(log2FC) greater than 1 and less than minus 1 were considered to be differentially expressed,
unless otherwise stated. False detection rate correction was performed using the Benjamini-Hochberg
method [25]. Results presented representative of two or more independent repeats and all error bars
are standard deviations.
2.11. Ethics Statement
All animal work was approved by the Beijing Association for Science and Technology (approval ID
SYXK (Beijing) 2007-0023; approval date: 30 August 2020) and conducted in accordance with the Beijing
Laboratory Animal Welfare and Ethics guidelines, as issued by the Beijing Administration Committee
of Laboratory Animals, and in accordance with the China Agricultural University Institutional Animal
Care and Use Committee guidelines (ID: SKLAB-B-2010-003, approval date: 30 August 2020).
3. Results
3.1. Non-Cytotoxic Application of TG Blocks Influenza A Virus Replication in Respiratory Epithelial Cells
To ascertain an innate immune role for TG on influenza A virus replication, NPTr cells, a neonatal
porcine tracheal epithelial cell line [26] (Figure 1A) and primary normal human bronchial epithelial
(NHBE) cells (Figure 1B) were primed with TG for a total duration 30 min and then infected with a
human USSR H1N1 virus. TG priming dramatically reduced progeny virus production 12 and 24 h
post-infection as determined by focus forming assays (FFAs) (Figure 1A,B). Viral M-gene RNA in
the culture media of TG-primed cells was also reduced relative to control cells, indicating an overall
reduction in progeny virus release from TG-primed cells (Figure 1C). TG priming was effective against
other influenza A subtypes, reducing progeny virus output in equine and canine H3N8 viruses in
MDCK cells (Figure 1D,E). Moreover, one passage of supernatants (sns) derived from initially infected
TG-primed NPTr cells (P1) to fresh TG-primed cells (P2) almost completely abolished progeny virus
production to around the threshold of viral detection, highlighting the highly potent antiviral effect of
TG (Figure 1F,G). Moreover, USSR H1N1 virus was subjected to 10 successive passages in NPTr cells in
the continuous presence of DMSO or sub-optimal TG (0.05 µM). The sensitivity of the first (P1) and
10th passaged virus (P10) to TG (30 min priming at 0.5 µM) remained unchanged as indicated by no
increase in progeny output after 10 passages (Figure 1H).
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Figure 1. Brief TG priming of NPTr and NHBE cells blocks progeny influenza virus production.
(A) NPTr cells and (B) NHBE cells were incubated for 30 min with TG or DMSO control at the indicated
concentrations, PBS washed and infected for 12 and 24 h, respectively, with USSR H1N1 virus at 0.5 MOI.
Spun supernatants (sns) were used to infect MDCK cells for 6 h in FFAs. Significance determined by
one-way ANOVA, relative to DMSO control. (C) NPTr cells and NHBE cells were primed with TG
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(0.5 and 0.01 µM, respectively) or DMSO for 30 min, and infected with USSR H1N1 virus (0.5 and
1.0 MOI, respectively) for 24 h. Culture media were then harvested to determine presence of viral
M-gene RNA. Significance determined by paired t-test. (D,E) MDCK cells were incubated for 30 min
with TG or DMSO control at the indicated concentrations, PBS washed and infected for 24 h with
(D) equine H3N8 and (E) canine H3N8 virus. TCID50 assay was performed to quantify virus output.
Significance determined by one-way ANOVA, relative to DMSO control. (F) P1 sns were derived from
0.5 µM TG or DMSO pre-primed (for 30 min) NPTr cells infected with stock virus (USSR H1N1 at
0.5 MOI) for 23 h. Fresh NPTr cells (P2) pre-primed with respective TG or DMSO were infected with
corresponding P1 sns for 23 h. Volume of P1 supernatants used was the same as the starting stock virus
volume. Significance based on mixed model analysis was relative to corresponding DMSO pre-primed
cells. (G) Total progeny virus yield from initial virus infection on P1 cells, pre-primed with DMSO
or TG, followed by sequential infection with P1 supernatants on P2 cells correspondingly pre-primed
with DMSO or TG. Significance based on mixed effect analysis was relative to corresponding DMSO
pre-primed cells. Log (total virus yield) displayed. Each % refers to reduction in virus output relative
to initial virus dose from TG priming. (H) At passage 1 (P1), cells were infected with 20 HA units of
USSR H1N1 virus for 2 h, PBS washed and cultured for 3 days in the continuous presence of 0.05 µM
TG or DMSO control in serum-free OptiMEM media, supplemented with TPCK trypsin at 0.2 µg/mL.
Spun P1 sns were used for the next passage; a total of 10 serial passages were completed. P1 and
P10 sns were subsequently used in duplicates to separately infect for 2 h NPTr cells, pre-infection
primed for 30 min with 0.5 µM TG or DMSO, washed with PBS and cultured in OptiMEM for a further
22 h, after which harvested sns were used in 6 h FFAs on MDCK cells to determine progeny virus
output expressed in percentage where corresponding DMSO control output was set at 100%. Two-way
ANOVA, Sidak’s multiple comparisons test, showed no significance (ns) in virus inhibition between P1
and P10 TG-derived sns. Significance determined by Mann Whitney test, relative to corresponding
DMSO control. * p <0.05, ** p <0.01, **** p <0.0001. All assays were in triplicates and were performed
three times.
The antiviral doses of TG used to prime NPTr and NHBE cells had no significant adverse effect
on cell viability, based on host ATP production (Figure 2A,C), and caspase 3/7 activity (Figure 2B,D).
The selectivity index (SI) of TG in virus inhibition in NHBE cells and NPTr cells was similarly high.
SI from 30 min of pre-infection TG priming of NHBE cells was 15,483 (cytotoxicity concentration50 (CC50)
(based on luminescence cell viability) = 22.93 µM, and inhibitory concentration50 (EC50) (based on virus
output, ffu/µL) = 0.001481 µM), and in NPTr cells was 8087 (CC50 = 34.41 µM, and EC50 = 0.004255 µM)
(Figure 2E–H).
Furthermore, continuous exposure of NPTr cells and NHBE cells to antiviral doses of TG (at 0.5 µM
and 0.005 µM, respectively) for 24 h not only showed no cytotoxic effect but appeared to confer some
improvement in cell viability during culture (Figure 3A,B). Pre-priming with 0.5 µM TG for only 30 min
did not reduce cell viability in uninfected or influenza virus-infected NPTr cells but showed improved
viability during the 20 h culture (Figure 3C,D).
Potential TG cytotoxicity was also evaluated in RNA-seq analysis (see Section 3.4), utilising
Ingenuity Pathway Analysis (IPA)-Tox, a capability tool within the IPA knowledge base, to predict
drug mechanisms of toxicity in uninfected or infected (0.8 MOI USSR H1N1, 12 h infection) NHBE cells.
In uninfected NHBE cells, TG priming (0.01 µM, 30 min) was not associated with any significant z-score,
describing the activation state of a biological function. In infected NHBE cells, the only significant
z-score associated with TG priming predicted decreased liver damage (z-score −2.2, overlap p-value
0.499, thereby providing further support for the non-cytotoxic nature of TG doses used to induce an
antiviral state. In summary, brief priming of cells with non-cytotoxic concentrations of TG strongly
inhibits influenza virus replication.
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cells. (A,B) NPTr cells and (C,D) NHBE cells were incubated in indicated concentrations of TG or in
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DMSO control for 30 min and (A,C) cell viability assays (CellTiter-Glo luminescent cell viability
assay) or (B,D) caspase 3/7 activity assays (Caspase-Glo 3/7 assay) performed 24 h later. Significance
determined by one-way ANOVA, relative to DMSO control. No significant change in cell viability
or caspase activity was found. (E) NHBE cells and (G) NPTr cells were incubated for 30 min in a
range of TG concentrations, PBS washed and infected for 24 h with USSR H1N1 virus at 1.0 MOI and
0.5 MOI, respectively. Spun sns were used to infect MDCK cells for 6 h in FFAs. EC50 was calculated
from progeny virus output (%) by non-linear regression. (F) NHBE cells and (H) NPTr cells were
incubated for 30 min in a range of TG concentrations, PBS washed and cell viability assay (CellTiter-Glo
luminescent cell viability assay) performed 24 h later. CC50 was calculated from relative cell viability
(%) by non-linear regression. SIs (CC50/EC50) for NHBE and NPTr cells are 15,483 and 8087, respectively.
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with RealTime-Glo™ MT Cell Viability Assay. Readings indicate duration of post mock or influenza
virus infection. Significance based on mixed effect analysis relative to corresponding DMSO control.
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
3.2. TG Promptly Induces an Extended Antiviral State Targeting Influenza Virus Post-Translationally
The duration of virus inhibition in NPTr cells from 30 min of TG pre-infection priming was ound to
last at least 48 h (Figure 4A). Furthermore, virus inhibition was similarly effective between pre-infection
and 6 h post-infection TG primed NPTr (Figure 4B), and NHBE cells (Figure 4C) (virus replication
cycle is around 6 h). Inhibition of progeny virus production in TG-primed NPTr and NHBE cells
was accompanied by little or no change in viral RNA (Figure 4D,E) and viral proteins (Figure 4F,G).
Collectively, the lack of substantive change in the expression of viral RNA and protein in infected cells
pre-primed with TG indicates that a key virus inhibition step occurred post-translationally, possibly
affecting viral protein processing or transport.
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infected for 2 h, PBS washed and cultured in fresh infection media overnight. Cells 6 h post-infection
were treated with TG for 30 min, washed with PBS and cultured in fresh infection media overnight.
Spun sns were used to infect MDCK cells for 6 h in FFAs. Significance determined by paired t-test
within each time point. (D,F) NPTr primed with (0.5 or 1.0 µM) and (E,G) NHBE cells primed with
TG (0.005 or 0.01 µM respectively) were subsequently infected with USSR H1N1 at 0.5 and 1.0 MOI
respectively for 24 h. (D,E) Total RNA extracted to determine M gene expression for all samples,
normalised to 18S rRNA. Significance determined by one-way ANOVA, relative to DMSO control.
(F,G) Protein lysates (DMSO and highest selected TG concentration) harvested at 24 h post-infection
were used to ascertain viral NP and M1 protein levels, normalised to beta-actin. Representative blots
displayed. Significance determined by paired t-test. * p < 0.05, **** p < 0.0001. All assays were in
triplicates and were performed three times.
Viral NP localisation in TG-primed NHBE cells was performed at 6 h post-infection (hpi).
Infected TG-primed NHBE cells exhibited reduced nuclear accumulation of viral NP; there was
more than three-fold reduction in mean nuclear to cytosolic localisation ratio in TG treated cells
(Figure 5), which suggests that transport of NP into the nucleus was impaired by TG priming. Thus,
brief TG priming promptly confers an extended antiviral state of at least 48 h and disrupts viral NP
protein trafficking.
3.3. TG in Mice Confers Protection Against Lethal Virus Challenge
As proof of principle for the antiviral use of TG in vivo, we examined its effects in mice
subjected to lethal PR8 H1N1 virus challenge. We found that mice treated with TG (30 ng)
orally (by gavage), before infection and once a day post-infection until 7 days post-infection (dpi),
showed improved survival (Figure 6A) (p = 0.0001). PR8 virus loads in lungs of TG treated mice
were significantly lower than those of corresponding control mice on 3 dpi and 5 dpi (Figure 6B).
The 30 ng/mouse/day (1.5µg/kg/day) dose was a small fraction of the reportedly safe oral (at ~97.62µg/kg
in PCT WO2003/049717) or parenteral (2500 µg/kg) [27] use of TG for other types of in vivo studies.
All PBS-DMSO control mice infected with PR8 H1N1 virus died by 9 days dpi whereas 4 out of 10
(40%) TG treated mice survived and showed progressive weight gain from 9 dpi, which also indicates
that the TG regime was not detrimental to growth (Figure 6A,C). Significant divergence in mean body
weight between TG treated and control mice was evident from 6 dpi (Figure 6C). It should be noted
that the antiviral dose of TG at 1.5 µg/kg/day had not been optimised in mice.
Gross difference in lung pathology between TG treated and control mice was clearly visible at 5 dpi.
Control lungs showed extensive contiguous hyperaemic consolidation, whereas lung lesions in TG mice
were more localised and restricted to the vicinity of virus entry site, indicating reduced virus spread
(Figure 6D). Less severe lung pathology seen in TG treated mice coincided with noticeably less cytosolic
presence of NP at 3 dpi and 5 dpi than corresponding controls (Figure 6E). Thus, oral administration of
TG in mice significantly reduced severity and virus shedding, and improved survival during lethal
influenza virus infection.
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Figure 5. Cytoplasmic NP localisation in TG primed cells. (A) NHBE cells were primed with DMSO
or 0.01 µM TG for 30 min, and infected with USSR H1N1 virus at 1.0 MOI for 6 h. Cells were
immunostained for viral NP (mouse anti-influenza A virus NP primary antibody detected by donkey
anti-mouse IgG H&L conjugated to Alexa Fluor 488 secondary antibody; green fluorescence) and nuclei
were stained with DAPI (blue fluorescence). Cells imaged with a Leica TCS SP8 confocal microscope
using a 63-time oil immersion objective (scale bar: 25 µm). (B) The ratio of nuclear to cytoplasmic
NP fluorescence signal in DMSO and TG-primed NHBE cells was calculated using Fiji (image J).
Significance determined by Mann Whitney test, relative to indicated DMSO control. **** p < 0.0001.
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Figure 6. TG in mice confers protection against lethal PR8 H1N1 virus challenge. (A) Survival of mice
post-infection treated each day with TG or PBS-DMSO control (n = 10 in each gro p). Kaplan-Meier
survival curves ar compare using the l g-rank (Mantel-C x) analysis. (B) Viral titres of lungs from
mice treated with TG or PBS-DMSO at 3dpi and 5dpi was determined by TCID50 assays (n = 3 in each
group). (C) Mean body weight changes post-infection was determined by daily monitoring (n = 10
in each group). (D) At 5 dpi, entire lungs of TG treated mice displayed much less extensive gross
pathology than those of control lungs. Blue outline demarcates boundary between apparent normal
and consolidated abnormal tissues. (E) Representative microscopic lung fields, (40-time magnification),
derived from similar anatomical sites taken at 3 and 5 dpi, showed that TG treatment resulted in less
diffused distribution of viral NP protein (less brown staining), and more frequent localisation of NP
than those in corresponding PBS-DMSO controls. Each mouse was infected at 1 × 102 TCID50 of PR8
virus. ** p < 0.01, *** p < 0.001.
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3.4. ER Stress Is a Dominant Driver of Host Antiviral Response to TG Priming
RNA-seq analysis, along with analytical use of IPA knowledge base, was performed to identify
antiviral processes elicited by TG pre-priming (0.01 µM, 30 min) of NHBE cells infected with 0.8 MOI
USSR H1N1 virus for 12 h. We found that the antiviral effects of TG are strongly linked to ER
stress-induced UPR [9,15]; it was the most highly enriched canonical pathway upregulated by TG
in uninfected cells (−log(p-value) 1.87 × 10, ratio 0.286), and infected cells (−log(p-value) 1.42 × 10,
ratio 0.286). In the absence of TG priming, between uninfected cells and infected cells primed
with DMSO, no genes associated with the canonical UPR pathway were significantly differentially
expressed due to infection, as can be examined in the full RNA-seq data set deposited in the GEO
database (GSE120730). UPR can promote host innate immune response and interfere with viral protein
translation [11,28,29]. We corroborated by qPCR that priming with non-toxic doses of TG strongly
elevated the basal expression of ER stress-associated genes (HSPA5, HSP90B1, and DDIT3) in NPTr
cells (Figure 7A–C) and NHBE cells (Figure 7D–F) in a dose-dependent manner.
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Figure 7. ER stress is a driver of host antiviral response to TG priming. (A–C) NPTr cells or (D–F)
NHBE cells were primed with DMSO or TG for 30 min at the indicated concentrations and infected
for 24 h with USSR H1N1 virus at 0.5 MOI. Total RNA was extracted from each sample for HSPA5,
HSP90B1 and DDIT3 detection, normalised to 18S rRNA. Indicated significance based 2-way RM
ANOVA relative to corresponding DMSO control. *p < 0.05 ** p < 0.01, ***p < 0.001 **** p < 0.0001.
Type I IFNs and their associated genes are essential for host defence against viruses [30] and can
be induced by ER stress [14]. RNA-seq analysis found over 80% of differentially expressed transcripts
of type I IFN-associated genes (biological process GO term 0060337) were more highly expressed
in TG-primed and infected NHBE cells than those from corresponding DMSO treated and infected
controls. This was exemplified by qPCR based on TG primed (0.01 µM, 30 min) NHBE cells infected
for 24 h with USSR H1N1 virus. Priming with TG consistently enhanced the expression of the type
I IFNβ1, interferon regulatory factor 9 (IRF9), a factor that transcriptionally activates type I IFN,
type I IFN-dependent retinoic acid-inducible gene 1 (RIG-I), and IFN-inducible 2′−5′-oligoadenylate
synthetase 1 (OAS1) and OAS3 genes (Figure 8A−E). Additionally, expression of type III IFNs (IFNL2
and IFNL3), was enhanced in TG-primed and infected NHBE cells (Figure 8F,G). The contribution of
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type I IFN to TG mediated antiviral activity was assessed in Vero cells, a cell type unable to produce
type I IFNs [31,32]. TG primed Vero cells did not significantly inhibit USSR H1N1 virus replication,
as indicated by viral copy number in culture media, at 24 and 48 hpi (Figure 8H).
To further assess the role of ER stress in TG-mediated antiviral response, we compared the antiviral
effect of tunicamycin, a well-established inducer of ER stress, with TG in NPTr cells. Tunicamycin
priming of NPTr cells at non-cytotoxic concentrations (at 0.5 or 1.0 µg/mL for 30 min) significantly
reduced progeny virus output (Figure S1A,B). Induction of ER stress-associated genes from tunicamycin
priming at 0.5 µg/mL was comparable to the use of TG at 0.5 µM, and at 1.0 µg/mL was approximately
3 to 8.2-fold higher than TG priming (Supplementary Figure S1C,D). Despite higher apparent ER stress,
progeny virus output from tunicamycin-primed cells was higher (thus less inhibitory) than TG-primed
cells (Figure S1B). This could be attributed to differential activation of ER stress UPR pathways by
tunicamycin and TG. Enhanced type I IFN-dependent gene expression induced by TG was not found
in tunicamycin-primed NPTr cells (Figure S1E,F). Differential activation of the type I IFN response by
TG-dependent and not tunicamycin-mediated ER stress has been previously reported [14]. Expression
of ER stress genes in TG, and tunicamycin-primed but not DMSO control cells was attenuated during
influenza virus infection, which might have been a virus effect to maintain viral protein production
(Figure S1C,D). Thus, ER stress per se contributes to the antiviral effects of TG priming.
Additional host antiviral processes induced by TG priming were further evident in the analysis of
1862 transcripts (encoded by 1468 genes) exclusively found in the differential comparison of TG-primed
infected vs. TG-primed uninfected NHBE cells (Figure 9A). This data set did not include genes
differentially expressed in infected DMSO versus uninfected DMSO treated controls. Using IPA,
a subset of 87 genes from the 1468 genes were identified as connected to RNA virus replication, 61 of
which were predicted, based on direction of differential expression, to reduce RNA virus replication
(z = −4.22, overlap p-value 2.36 × 10−11). Forty-three out of the same 87 genes were specifically
associated with influenza A virus replication of which 31 were predicted by IPA to specifically reduce
influenza A replication (z = −2.813, overlap p-value 9.82 × 10−6). The 61 differentially expressed
antiviral genes exclusive to TG priming and infection could be further classified into several functional
categories. Twenty-one genes (34%) were involved in disruption of protein transport (nuclear,
cytoplasmic, secretory or budding); 11 genes (18%) were related to reduced ubiquitinase or kinase
function; 8 genes (13%) were associated with enhanced type I/III IFN-associated response; and 8 genes
were connected to reduced RNA production or processing. Within the group of 1862 transcripts,
sumoylation (−log(p-value) 5.27, ratio 0.198) and protein ubiquitination (−log(p-value) 5.14 ratio 0.136)
were the seventh and eighth most enriched canonical pathways identified (Figure 9B). As influenza viral
proteins utilise host post-translational modification machinery to support their replication, including
sumoylation and ubiquitination [33–35], it is likely that post-translational viral protein modification is
part of a multifaceted host antiviral response induced by TG.
Taken together, TG-induced ER stress appears as a key driver responsible for a number of host
antiviral processes that include an enhanced type I/III IFN response and involve dysregulation of
post-translational viral protein modification.
Viruses 2020, 12, 1093 16 of 21
Viruses 2020, 12, x FOR PEER REVIEW 16 of 22 
 
IFNβ1, interferon regulatory factor 9 (IRF9), a factor that transcriptionally activates type I IFN, type I 
IFN-dependent retinoic acid-inducible gene 1 (RIG-I), and IFN-inducible 2′−5′-oligoadenylate 
synthetase 1 (OAS1) and OAS3 genes (Figure 8A−E). Additionally, expression of type III IFNs (IFNL2 
and IFNL3), was enhanced in TG-primed and infected NHBE cells (Figure 8F,G). The contribution of 
type I IFN to TG mediated antiviral activity was assessed in Vero cells, a cell type unable to produce 
type I IFNs [31,32]. TG primed Vero cells did not significantly inhibit USSR H1N1 virus replication, 
as indicated by viral copy number in culture media, at 24 and 48 hpi (Figure 8H). 
 
Figure 8. TG priming enhanced type I/III IFN-dependent gene expression. (A–G) NHBE cells were 
incubated for 30 min with DMSO or 0.01 µM TG and subsequently infected with USSR H1N1 virus 
Figure 8. TG priming enhanced type I/III IF -dependent gene expression. (A–G) NHBE cells were
incubated for 30 min with DMSO or 0.01 an s bsequently infected with USSR H1N1 virus
at 0.5 MOI for 24 h. Total RNA was extracted from each sample for type I/III IFN and indicated
associated gene expression, normalised to 18S rRNA. Significance determined by two-way ANOVA,
relative to corresponding DMSO control. (H) Vero cells were primed with TG as indicated for 30 min,
washed twice with PBS and infected with USSR virus 0.5 MOI. Viral RNA extraction was performed on
culture media at 24 and 48 hpi followed by one-step reverse transcription qPCR to detect the relative
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4. Discussion
The problem of drug resistance faced by current and near-market antivirals is a serious concern,
as exemplified by the alarming emergence of resistance to the recently approved antiviral baloxavir
marboxil (Xofluza) [2,36,37]. Targeting the virus proteins directly applies a strong selection pressure
for the emergence of drug-resistance escape mutants [38,39]. Host-dependent therapies are a potential
alternative to targeting the virus proteins directly and are not readily overcome by the highly mutable
influenza virus [5].
We discovered that SERCA inhibitor TG elicits a range of host antiviral defences including an
enhanced type I/III IFN response that is highly inhibitory to influenza A virus replication. Brief TG
exposure, at non-toxic levels, promptly induces a prolonged (≥48 h) antiviral state that is potentially
of prophylactic and therapeutic importance. Ten passages of USSR H1N1 virus in the continuous
presence of suboptimal concentration of TG did not reduce viral sensitivity to subsequent antiviral
TG priming, suggesting that TG treatment may be less susceptible to drug resistance. Crucially, daily
oral dose of TG in mice, which at 30 ng was a fraction of the reported oral (in PCT WO2003/049717) or
parenteral [27] doses given to mice, significantly reduced severity and improved survival in lethal
influenza virus infection.
TG triggers three closely connected signalling events: (1) ER Ca2+ store depletion, (2) ER stress
and (3) extracellular Ca2+ entry through the store-operated Ca2+ channel. Release of intracellular store
Ca2+ was found to be more necessary than extracellular Ca2+ influx in the inhibition of henipavirus
replication using a number of Ca2+ mobilisation compounds including TG whose antiviral effect was
reduced by the Ca2+ chelator, BAPTA-AM at 10 µM [40]. An earlier report showed that inhibition of
the IRE1 pathway with tauroursodeoxycholic acid blocks influenza A virus replication [12]. On the
contrary, ER stress-activated IRE1αwas found to promote antiviral RIG-I-IFN-β signalling in FMD virus
inhibition [14–16]. Likewise, TG treatment of U2OS cells infected with tick-borne encephalitis virus
was found to lead to early IFNβ induction via activated IRE1 [29]. In TG-induced UPR, activated PERK
by inactivating the eIF2α subunit rapidly attenuates global protein synthesis that includes that of
influenza virus protein synthesis [41]. Although TG-induced UPR is a primary antiviral response to
influenza virus inhibition, future studies will need to examine the relative importance of each of the
three arms of the UPR.
Our data indicate that TG priming elevates type I/III IFN-associated responses in influenza
virus-infected cells. A previous report found stimulating an increase in cytosolic Ca2+ in the absence
of ER stress did not induce phosphorylation of IRF3, and that ER stress involving Ca2+ mobilisation,
requiring TBK1 and STING, activates IRF3 [14]. Activation of the STING-TBK1-IRF3 signalling pathway
can be inhibited by an intracellular Ca2+ chelator [42]. Interestingly, ionomycin stimulated extracellular
Ca2+ influx was found to inhibit STING mediated production of IFNβ [42]. These findings support the
suggestion that TG mediated ER stress from ER store Ca2+ efflux promotes the activation of type I/III
IFN signalling. The necessity of a functional type I IFN response in a TG induced antiviral state was
evident by its ineffectiveness in inhibiting influenza virus replication in Vero cells, a monkey kidney
epithelial cell line incapable of producing type I IFNs. Promoting an enhanced type I/III IFN-associated
response to infection could also be of paracrine importance in converting neighbouring uninfected
cells into a highly activated antiviral state, a containment feature that was evident in infected lungs of
TG treated mice.
We identified a TG-specific host antiviral signature of 61 genes whose direction of differential
expression is predicted to be consistent with reduced RNA virus replication. Just over 50% of the
61 signature genes are involved in post-translational protein processing (including ubiquitination and
sumoylation) or transport across different organelles. Sumoylation of influenza viral proteins, NS1 [43],
NP [33] and M1 [34] is either necessary for or promotes virus replication at post-translational stages
involving viral protein stability, trafficking or assembly. Ubiquitinaton of influenza viral polymerase
complex stimulates polymerase function [44]; and ubiquitination of influenza virus M2 is crucial for
virus assembly and virus induced cell death [35]. Thus, reduced or dysregulated ubiquitination or
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sumoylation of viral proteins can be expected to interfere with viral protein transport and assembly.
Future work will benefit from developing an in-depth knowledge of the impact of TG exposure on the
host protein processing machinery. Finally, given the structural complexity of TG, there is a possibility
that it could also activate host antiviral processes that are independent of its impact on ER stress.
In summary, we propose that TG, in orchestrating a spectrum of host antiviral defences, are not
readily overcome by virus mutation, and is potentially a viable host-centric antiviral for the treatment
of influenza A virus infection without the inherent problem of drug resistance.
5. Patents
The use of TG and other structurally-related compounds in antiviral therapy is covered by patent
PCT/GB2019/050977.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/12/10/1093/s1,
Figure S1: TG and tunicamycin mediated ER stress.
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